Target intelligence / Profile preview

ETS proto-oncogene 1, transcription factor (ETS1)

Target
ETS1
Molecular classification
Transcription factor
01

Overview

ETS proto-oncogene 1, transcription factor (ETS1) is a member of the ETS family of transcription factors characterized by a conserved ETS DNA-binding domain that recognizes GGAA/T motifs in gene promoters[1][2]. ETS1 regulates gene expression of genes involved in cell proliferation, differentiation, migration, apoptosis, immune responses, and angiogenesis[1][2]. It plays a key role in lymphoid lineage differentiation and in responses to extracellular signals via MAPK/ERK and PI3K/Akt pathways[1][2]. Aberrant expression or activity of ETS1 is linked to tumor progression, metastasis, and immune escape, making it a biomarker and potential therapeutic target in oncology[2]. ETS1 also interacts with DNA repair pathways and proteins (such as PARP1 and DNA-PK), impacting DNA damage resistance and cell survival[1]. Because ETS1 influences many vital processes in normal and diseased tissues, strategies modulating its function must account for complex physiological roles[1][2][3].

Other names
Protein C-ets-1EWSR2FLJ10768ETS-1p54Avian erythroblastosis virus E26 (v-ets) oncogene homolog-1c-ets-1v-ets avian erythroblastosis virus E2 oncogene homolog 1v-ets avian erythroblastosis virus E26 oncogene homolog 1
02

Mechanism of action

Small molecules or oligonucleotides targeting DNA-binding or protein-protein interaction surfaces to modulate ETS1 activity (either inhibit or enhance its transcriptional regulatory effects). Epigenetic modifiers affecting ETS1 binding and downstream gene expression.

03

Biological functions

Regulation of gene expressionCell proliferationDifferentiationMigrationApoptosisAngiogenesisImmune responseDNA repair regulation
04

Disease associations

CancerImmune disordersFibrosisDiabetic retinopathy
05

Safety considerations

Broad regulatory role in development and immune function raises concern about off-target effects, including immunosuppression, impaired differentiation, and possible effects on DNA repair and cell survival
06

Interacting drugs

None with direct, clinically approved inhibitors at present; several small-molecule and experimental compounds under investigation for modulating ETS transcription factors, but no standard drugs
07

Biomarkers

Differential ETS1 expression as a molecular marker for tumor diagnosis and prognosis in various cancers

Beyond the preview

Go deeper on ETS proto-oncogene 1, transcription factor (ETS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETS proto-oncogene 1, transcription factor (ETS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call